Recent Company News

• 02:25 AM ET Sep 29, 2025
  

  Hikma Pharmaceuticals and Gedeon Richter receive FDA approval for denosumab biosimilars Enoby and Xtrenbo (1644.0000p, 0)

• 08:00 PM ET Sep 28, 2025
  

  Mayne Pharma Group notes Australian government approves NEXTSTELLIS for Pharmaceutical Benefits Scheme reimbursement (A$5.16, 0.00)

• 10:12 PM ET Aug 20, 2025
  

  RBC Capital Markets transfers ALM.SM, BIOA.B.SS, FYB.GR, others

• 01:54 AM ET May 14, 2025
  

  Mayne Pharma Group confirms the FDA Untitled Letter does not impact its ability to sell and distribute NEXTSTELLIS in the United States (A$5.93, -0.86)

• 11:09 AM ET Apr 25, 2025
  

  EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Gedeon Richter's Junod (10860.00Ft, 0.00)

• 10:37 AM ET Apr 25, 2025
  

  EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Yaxwer (10870.00Ft, 0.00)

• 09:30 AM ET Apr 10, 2025
  

  Gedeon Richter upgraded to buy from hold at HSBC, we're told (timing uncertain) (10340.00Ft, +250.00)

• 11:32 AM ET Oct 24, 2024
  

  AbbVie and Gedeon Richter announce new collaboration for the discovery and development of novel targets for neuropsychiatric conditions ($189.71, +1.83)

• 07:37 AM ET Oct 09, 2024
  

  Bio-Thera, Gedeon Richter execute exclusive commercialization agreement for BAT2206 for EU, UK, Switzerland, other countries (CNY 25.58, 0.00)

• 08:02 AM ET Sep 04, 2024
  

  AbbVie's VRAYLAR (cariprazine) receives positive reimbursement recommendation by Canada's drug agency for the treatment of schizophrenia ($197.69, 0.00)